Governments Fall Behind in Race to Stem Antimicrobial Resistance

Without decisive action, there could be 10m deaths a year due to AMR by 2050 — and a cumulative cost to the global economy of $100tn

Five years ago, the UN General Assembly adopted a landmark declaration urging global action against growing anti­microbial resistance (AMR) — which many still view as one of the greatest threats to public health in the 21st century.

The move followed a groundbreaking review of antibiotic resistance commissioned by the UK government from the economist Jim O’Neill, the findings of which continue to be widely cited. Without decisive action, there could be 10m deaths a year due to AMR by 2050 — and a cumulative cost to the global economy of $100tn.

Yet 2016 was a high watermark for political and public engagement with AMR. While the subsequent five years have seen some new funding for antibiotics research and development — as well as initiatives to slow the evolution of AMR by restraining excessive use of existing drugs in medicine and agriculture — progress has not been made at the scale needed.

“Comparing the many commitments made in the UN declaration with how governance and financial initiatives for AMR has developed in reality, progress — and particularly the pace — has been truly disappointing,” says Otto Cars, professor of infectious diseases at Uppsala University, and a member of the UN Interagency co-ordination Group on AMR set up after the declaration.

The Covid-19 pandemic has thrown the failure to act on AMR into sharp relief. “Antibiotic resistance is not like Covid-19 — it will not be an unpredictable pandemic,” says Cars, who also founded the international AMR network ReAct.

“The world already knows what it must do to prevent and manage it. We just don’t have the broad political will to tackle it.

“Yet, if we can’t convince governments at this point to prioritise and invest in the prevention of health disasters that we know are approaching in the foreseeable future, what has the world really learned from Covid-19?”

The World Health Organization’s annual Antibacterial Pipeline Report in April found that none of the 43 antibiotics currently in clinical development sufficiently addresses drug resistance in the most dangerous bacteria.

“The persistent failure to develop, manufacture and distribute effective new antibiotics is further fuelling the impact of AMR and threatens our ability to successfully treat bacterial infections,” says Hanan Balkhy, WHO assistant director-general for AMR.

A new AMR Preparedness Index, launched in June by the Global Coalition on Aging and the Infectious Diseases Society of America, provided more evidence of what it called “a broad failure to match public promises with the concrete actions needed to avert the growing crisis”. The index scored the world’s 11 largest economies against seven AMR criteria. The worst national performers were Brazil, China and India; least bad was the UK.

Since the 1980s, the stock of effective antibiotics has depleted gradually as bacteria evolve and build up resistance. Replenishing the pipeline requires both “push” and “pull” financial incentives.

Push — which means funding research by biotech companies and universities to discover new antibiotics and carry out initial clinical trials — is performing better than pull, which instead rewards pharmaceutical companies for taking antibiotics through late-stage clinical trials and on to the market.

Several organisations set up with public, private and charitable funding are supporting research into new antibiotics. The most active backers of antibiotic R&D include Carb-X, GARDP, Repair Impact Fund and AMR Action Fund.

There has been much less progress on the pull side. Marketing new antibiotics would bring in little conventional sales revenue, as the drugs would be reserved for use in small quantities in short courses on patients whose infection is not treatable with existing products.

A few countries, including the US and UK, are exploring subscription-style incentives, in which companies would be paid upfront for developing effective new antibiotics in ways that are not linked directly to sales volumes. But none of the pull initiatives is yet on a scale sufficient to make much impact.

A report published by the Access to Medicine Foundation in Amsterdam in June showed that innovative antibiotics and their producers must bridge two distinct funding “valleys of death” before the drugs can reach patients.

One is in the earlier stages, when venture capitalists are unwilling to support a new antibiotic with no promising return on investment. The second is the “commercial valley of death” when an approved drug reaches the market but lacks sufficient sales revenues.

Oxford Drug Design, an Oxford university spinout, exemplifies the problem. Its technology — based on inhibiting enzymes called Aminoacyl-tRNA which play a key role in protein synthesis — is leading to promising antibiotics for treating drug-resistant infections.

“We have received generous grants from Carb-X and Innovate UK which have enabled us to make good technical progress, but that does not cut the ice with venture capitalists,” says Paul Finn, the company’s chief scientist.

“It has been well-nigh impossible to raise money to take our molecules into the clinic. We are almost forced to move away from AMR and into other areas where we can apply our technology, particularly cancer and fibrosis.”

Others are in a worse predicament than Oxford Drug Design. “Many companies go bankrupt before they can launch their products and some fail even after reaching this milestone,” the Access to Medicine report says.

“It is clear that the innovators of such drugs urgently need a stable economic and policy environment suitable for developing and responsibly delivering new antimicrobials.”

Source: Financial Times

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

A Bipartisan Bill Could Prevent The Next Pandemic

In Washington, Republicans and Democrats are typically at loggerheads when it comes to healthcare policy. Just consider the recent Inflation Reduction Act, which made extensive changes to Medicare and also extended Affordable Care Act subsidies. Every single congressional Democrat voted for the legislation, while every single member of the GOP voted against it. But occasionally, a bill is such an obviously good idea, and so desperately needed, that it commands significant bipartisan support. The PASTEUR Act, co-sponsored by 31 Democrats and 31 Republicans in the House and two members of each party in the Senate, is just such a bill.

Korea Must Act Now to Combat Growing AMR Threat

Public officials are overlooking one of the gravest long-term threats to the Korean people, the health system, and economy: antimicrobial resistance (AMR). Some pathogens ― bacteria, fungi, parasites, and viruses ― have evolved strains that resist the antimicrobial medications we currently have available to fight them. Health care professionals often must watch helplessly as patients succumb to infections that antibiotics could once have easily beaten. They know that new antimicrobials, including and especially antibiotics, could easily gain the victory ― but they have none at their disposal.

Policy Statement on the Impact of Price Negotiations on Innovation, Healthy Aging and Equity

As the CEO of the Global Coalition on Aging (GCOA) and a newly formed cross-sector Alliance for Health Innovation, we write to express our deep concern with the current legislation that allows for price “negotiations” in Medicare – a thinly veiled signal for America’s plunge into price controls that will have a devastating and adverse impact on biopharmaceutical innovation and our nations’ ability to support healthy aging. 

Ignoring the ‘Silver Economy’ May Be Getting Costly for Brands

In an ad for Airbnb that premiered earlier this year, a couple checks into a cozy Spanish villa. To the tune of Jay-Z's cover of "Me and My Girlfriend," the ad shows the pair settling into their rental and setting their collective dial to chill. They play ping-pong, sip some wine, and get ready for a night on the town. They're also in their 80s, celebrating their 57th wedding anniversary. In no way does the ad characterize the couple as elderly or portray them as needing special aid or services — they are just active people who happen to be old. It's a rare example of ads featuring a realistic depiction of aging.

Health Equity Promise and That Innovation Thing

President Biden has pledged his administration to defeat cancer, Alzheimer’s, and other diseases that target America’s aging population. To achieve these lofty goals, bold words must be backed up by bold actions.

Roundtable Report Highlights Importance of Immunizing Canada’s Caregivers Against Influenza, Identifying Challenges and Opportunities to Protect This Critical Group

The Global Coalition on Aging (GCOA) today released a report summarizing key insights from an expert roundtable on vaccinating Canada’s caregivers against influenza. The roundtable, held virtually, brought together leading Canadian health policy experts, family caregivers, patient advocacy groups, aging experts, and other thought leaders to discuss challenges and strategies to reach this critically important yet hard-to-reach group.